Assessment of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Levels in Type 2 Diabetes Mellitus Patients in North Sumatera, Indonesia doi.org/10.26538/tjnpr/v5i11.4
Main Article Content
Abstract
Chronic hyperglycemia in type 2 diabetes mellitus causes endothelial cell dysfunction vascularization disorder and due to hypoxic condition, marked by hypoxia inducible factor-1 α (HIF-1α) and promote neovascularization and induce the secretion of vascular endothelial growth factor (VEGF). This study was aimed at evaluating the correlation between the HIF-1α and VEGF levels in type 2 diabetes mellitus patients. A cross-sectional analytic method was employed in the research. Eighty-nine patients with type 2 diabetes mellitus from various public health clinics in Medan, North Sumatera, Indonesia were recruited. Body mass index, blood pressure, disease duration, family history, and medical treatment were recorded. Also, blood samples were collected from the type 2 diabetes mellitus patients for laboratory analysis. The levels of blood sugar, glycosylated hemoglobin, HIF-1α, and VEGF were evaluated. The results revealed that the minimum HIF-1α level was 0.52 μL/dL and the maximum was 13.45 μL/dL, with a mean value of 1.93 μL/dL and SD of 2.46 μL/dL. Similarly, the lowest VEGF level was 111.64 μL/dL, while the highest was 22052.61 μg/dL, with a mean of 931.49 μg/dL and SD of 2405.95 μg/dL. The finding of this study indicated that there was a significant (p<0.005) correlation between the HIF-1α and VEGF levels in the patients with type 2 diabetes mellitus.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Ighodaro O and Adeosun A. Vascular complications in diabetes mellitus. Kidney. 2018; 1 (2):16-30.
Takeda Y, Matoba K, Sekiguchi K, Nagai Y, Yokota T, Utsunomiya K, Nishimura R. Endothelial dysfunction in diabetes. Biomed. 2020; 8(7):182-187.
Amalia L, Parwati I, Rizal A, Panigoro R, Gamayani U, Rasyid A, Atiik N. Hypoxia Inducible Factor (HIF) 1-α and Vascular Endothelial Growth Factor (VEGF) at Acute Ischemic Stroke. J Neuroanestesi Indon. 2019; 8(3):226-232.
Feng S, Bowden N, Fragiadaki M, Souilhol C, Hsiao S, Mahmoud M, Evans PC. Mechanical activation of hypoxia-inducible factor 1α drives endothelial dysfunction at atheroprone sites. Arterioscl Thromb Vasc Biol. 2017; 37(11):2087-2101.
Richner M, Ferreira N, Dudele A, Jensen TS, Vaegter CB, Gonçalves NP. Functional and structural changes of the blood-nerve-barrier in diabetic neuropathy. Front Neurosci. 2019; 12(1038):1-9.
Ding ZN, Dong ZR, Chen ZQ, Yang YF, Yan LJ, Li HC, Li T. Effects of hypoxia‐inducible factor‐1α and hypoxia‐inducible factor‐2α overexpression on hepatocellular carcinoma survival: A systematic review with metaanalysis. J Gastroenterol Hepatol. 2021; 6(6):1487-1496.
Majumder S and Advani A. VEGF and the diabetic kidney: More than too much of a good thing. J Diab Complic. 2017; 31(1):273-276.
Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, Yu JQ. Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother. 2018; 27(101):510-517.
Azimi I. The interplay between HIF-1 and calcium signaling in cancer. Int J Biochem Cell Biol. 2018; 97 (10):73-74.
Sellami N, Lamine LB, Turki A, Sarray S, Jailani M, AlAnsari AK, Almawi WY. Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: A casecontrol study. Cytokine. 2018; 106(6):29-34.
Ahmed AJ, Majeed SR, Obaid HM. Biochemistry and molecular cell biology of diabetic complications. System Rev Pharm. 2020; 11(11):850-860.
Shukla R, Pandey N, Banerjee S, Tripathi YB. Effect of extract of Pueraria tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats. Biomed Pharmacother. 2017; 93 (15):276-285.
Zhang Q, Fang W, Ma L, Wang ZD, Yang YM, Lu YQ. VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 +diabetes: A cohort study. Med. 2018; 97(15):1-6.
Román CL, Maiztegui B, Mencucci MV, Ahrtz L, Algañarás M, Del Zotto H, Flores LE. Effects of islet neogenesis associated protein depend on vascular endothelial growth factor gene expression modulated by hypoxia-inducible factor 1-alpha. Peptides. 2019;
(117):44-50.
Wang J and Ye S. Up-regulation of hypoxia-inducible factor-1α in patients with diabetic nephropathy. Niger J Clin Pract. 2019; 22 (6):750-753.
Alique M, Sánchez-López E, Bodega G, Giannarelli C, Carracedo J, Ramírez R. Hypoxia-inducible factor-1α: the master regulator of endothelial cell senescence in vascular aging. Cells. 2020; 9(1):195.
Kiani AA, Nazarabad VH, Ahmadi K, Anbari K, Ahmadi BB. Polymorphisms of endothelial nitric oxide synthase and hypoxia-inducible factor 1 alpha genes play a role in susceptibility to coronary artery disease. Biomed Res Ther. 2018; 5(9):2688-2688.
Rusdiana R, Savira M, Siregar KB, Widjaja SS, Ardinata D. Correlation of hypoxiaInducible factor-1α Level with control glycemic in type 2 mellitus patients with
malignancy and without malignancy. Open Access Maced J Med Sci [Internet]. 2020 Apr 10 [cited 2020Sep.20]; 8(B):408-13. Available from: https://www.idpress.eu/mjms/article/view/3926.
McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Rad Biol Med. 2018; 125 (17):15-24.
Semenza GL and Prabhakar NR. The role of hypoxia‐inducible factors in carotid body (patho) physiology. J Physiol. 2018; 596(15):2977-2983.
Mylonis I, Simos G, Paraskeva E. Hypoxia-inducible factors and the regulation of lipid metabolism. Cells. 2019; 8(3):214.